NeuroBo Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2014
Net Income	-16.58	-12.47	-13.97	-15.28	-29.68	-21.31	Upgrade
Depreciation & Amortization	0.01	0.01	0.03	0.07	0.07	0.02	Upgrade
Share-Based Compensation	0.4	0.22	0.85	0.66	0.7	0.12	Upgrade
Other Operating Activities	1.47	1.44	1.37	-0.58	18.15	14.14	Upgrade
Operating Cash Flow	-14.69	-10.8	-11.71	-15.13	-10.76	-7.04	Upgrade
Capital Expenditures	-0.05	-0.05	0.01	-0	-0	-0.21	Upgrade
Acquisitions	0	0	0	-0.58	0.07	-5.84	Upgrade
Investing Cash Flow	-0.05	-0.05	0.01	-0.59	0.07	-6.06	Upgrade
Share Issuance / Repurchase	0	0	32.25	24.12	7.55	0	Upgrade
Other Financing Activities	-0.08	-0.08	-3.57	-2.09	-0.7	24.17	Upgrade
Financing Cash Flow	-0.08	-0.08	28.68	22.03	6.86	24.17	Upgrade
Exchange Rate Effect	0	0	0	-0.01	0	0.01	Upgrade
Net Cash Flow	-14.83	-10.93	16.98	6.31	-3.84	11.07	Upgrade
Free Cash Flow	-14.75	-10.85	-11.7	-15.14	-10.77	-7.25	Upgrade
Free Cash Flow Per Share	-2.90	-2.14	-36.38	-156.98	-159.37	-333.24	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).